Latest News and Press Releases
Want to stay updated on the latest news?
-
60 Degrees Pharma (Nasdaq: SXTP) will sponsor a study using tafenoquine, an FDA-approved malaria drug, to treat canine babesiosis, a tick-borne disease.
-
60 Degrees Pharma advises of expected FDA response a month later than anticipated. Prepares for June 1, 2024, start of trial of tafenoquine for babesiosis.
-
60 Degrees Pharmaceuticals will Sponsor Pre-Clinical Studies ofTafenoquine Use in Candida spp, Including Candida auris
-
Kristen Landon appointed Chief Commercial Officer at 60 Degrees Pharma leading ARAKODA® relaunch for malaria prevention and expanded tick-borne strategy.
-
60 Degrees Pharmaceuticals (Nasdaq: SXTP) closes $2.4 million public offering.
-
60 Degrees Pharma announces a $2.4 mil public offering, with funds to be used for working capital, relaunching ARAKODA for malaria prevention, and research
-
Post-FDA meeting, 60 Degrees Pharma plans pivotal study of tafenoquine in hospitalized babesiosis patients, aiming to start in summer 2024. #biotech #SXTP
-
60 Degrees Pharma (Nasdaq: SXTP) announced that it has regained compliance with Nasdaq minimum listing requirements.
-
60 Degrees Pharma has received IRB approval for a Phase IIA study evaluating tafenoquine's efficacy in treating hospitalized babesiosis patients, while the
-
60 Degrees Pharma (Nasdaq: SXTP) will meet with FDA to discuss its proposed Phase II study on the use of tafenoquine for babesiosis.